An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
Public ClinicalTrials.gov record NCT02320032. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1, Randomized, Open-Label Study Evaluating the Pharmacokinetics of Various Dosing Regimens of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will evaluate the safety, tolerability, and pharmacokinetics (PK) of various doses and dosing intervals of aripiprazole lauroxil.
Study identification
- NCT ID
- NCT02320032
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 140 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 30, 2014
- Primary completion
- Mar 31, 2016
- Completion
- Mar 31, 2016
- Last update posted
- Aug 28, 2018
2014 – 2016
United States locations
- U.S. sites
- 16
- U.S. states
- 9
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Alkermes Investigational Site | Little Rock | Arkansas | 72211 | — |
| Alkermes Investigational Site | Cerritos | California | 90703 | — |
| Alkermes Investigational Site | Garden Grove | California | 92845 | — |
| Alkermes Investigational Site | Washington D.C. | District of Columbia | 20016 | — |
| Alkermes Investigational Site | Lauderhill | Florida | 33161 | — |
| Alkermes Investigational Site | Leesburg | Florida | 34748 | — |
| Alkermes Investigational Site | Maitland | Florida | 32751 | — |
| Alkermes Investigational Site | Oakland Park | Florida | 33334 | — |
| Alkermes Investigational Site | Tampa | Florida | 33613 | — |
| Alkermes Investigational Site | Atlanta | Georgia | 30308 | — |
| Alkermes Investigational Site | Chicago | Illinois | 60640 | — |
| Alkermes Investigational Site | Hoffman Estates | Illinois | 60169 | — |
| Alkermes Investigational Site | St Louis | Missouri | 63118 | — |
| Alkermes Investigational Site | Marlton | New Jersey | 8053 | — |
| Alkermes Investigational Site | Austin | Texas | 78754 | — |
| Alkermes Investigational Site | Dallas | Texas | 75243 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02320032, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 28, 2018 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02320032 live on ClinicalTrials.gov.